SPDL1 and neoplasm: Other promising serum-based biomarkers include soluble PD-L1 (sPD-L1) (16), circulating tumor cells (CTCs) (17), blood tumor mutational burden (bTMB), or circulating tumor DNA (ctDNA) (18).